It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage biopharma committed to transforming the treatment of acute organ injury and chronic liver diseases with its therapies based on its epigenetic regulator program
- Lead asset= DUR-928 is in P2 of development for Alcoholic Hepatitis (AH) and P1 for NASH (an advanced form of fatty liver disease)
- DUR-928 can be administered orally and intravenously